- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about NVO
Recent news which mentions NVO
Hims & Hers Stock Dropped: Here's What You Need to Know
October 24, 2024
From Motley Fool
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
October 23, 2024
From Benzinga
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
From Benzinga
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
October 22, 2024
From Benzinga
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
October 21, 2024
From Benzinga
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
October 18, 2024
From Benzinga
Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
October 18, 2024
From Benzinga
Behind the Scenes of Novo Nordisk's Latest Options Trends
October 17, 2024
Tickers
NVO
From Benzinga
Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
October 17, 2024
From Benzinga
'Miracle' Weight Loss Drug Ozempic And Similar Drugs Reduce Alcohol And Opioid Overdose, Study Reveals
October 17, 2024
From Benzinga
From Benzinga
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
October 16, 2024
From Motley Fool
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
October 15, 2024
From Benzinga
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
October 14, 2024
From Benzinga
3 No-Brainer Growth Stocks to Buy in October
October 13, 2024
From Motley Fool
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
October 11, 2024
From Benzinga
From Benzinga
From Benzinga
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
October 10, 2024
From Benzinga
2 No-Brainer Dividend Growth Stocks to Buy Right Now
October 10, 2024
From Motley Fool
Got $5,000? These 3 Growth Stocks Are on Sale Right Now.
October 09, 2024
From Motley Fool
What's Going With WeightWatchers Stock On Wednesday?
October 09, 2024
From Benzinga
Prediction: 3 of Wall Street's Most Influential Stocks Can Plunge if Kamala Harris Wins in November
October 08, 2024
From Motley Fool
Billion-Dollar News for Eli Lilly Stock Investors
October 07, 2024
From Motley Fool
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
October 07, 2024
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.